Samuel Agresta - 26 Jan 2022 Form 4 Insider Report for Foghorn Therapeutics Inc. (FHTX)

Role
Chief Medical Officer
Signature
/s /Allan Reine, M.D., Attorney-in-Fact
Issuer symbol
FHTX
Transactions as of
26 Jan 2022
Transactions value $
$0
Form type
4
Filing time
28 Jan 2022, 15:27:31 UTC
Previous filing
11 Jun 2021
Next filing
16 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FHTX Stock Option (right to buy) Award $0 +125,000 $0 125,000 26 Jan 2022 Common Stock 125,000 $14.87 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vested as to 25% of the underlying shares of common stock on January 26, 2023, the first anniversary of the of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested.